Recent Advances in Veterinary Orthobiologics
Wed, 02 July, 2025
02:00 pm - 04:00 pm
(Your Local Time Zone)
Species
Equine
Contact Hours
2
Language
English
Sponsors
Discipline
Orthopaedics
Sports Medicine
Growth Partners
North America
Europe
Veterinary Partners
Global
North America
Europe
Middle East & Africa
Asia-Pacific
Joint diseases and tendon injuries are the most common injuries reported in horses across all levels of equine disciplines. These injuries often result in lameness, which can lead to either a temporary or permanent inability to perform at a high level in competition.
Orthobiologics are a particular form of biological products that have their use in the area of musculoskeletal injuries including osteoarthritis and tendon/ligament injuries. In general, orthobiologics focus on using the body’s own mechanisms. Orthobiologics can generally be classified into 2 categories: autologous and allogeneic. Autologous orthobiologics have been collected and processed for use on the individual itself. Allogeneic orthobiologics can be collected from rigorously preselected individuals of the same species and then prepared with a patented process, tested, and released, ready to use in a different individual.
The current presentation focuses on the composition and mode of action of platelet-rich plasma (PRP) and Alpha 2 macroglobulin (A2MG) using different preparation methods. Furthermore, in a second part different case reports using allogeneic orthobiologics are being discussed.
Cedric Bocqué was born on March 5, 1989. Throughout his youth, he was a passionate rider in both eventing and jumping. This passion drove him to follow his dream: to become a veterinarian. After completing his studies, he did an internship at an equine clinic, after which he started working as an ambulatory equine veterinarian. However, Cedric's main goal was to specialize in orthopedics.
To achieve this, he not only followed the prestigious ISELP program but also gained
experience with leading orthopedic specialists in both Europe and the United States to
deepen his knowledge in the field. Upon returning, Dr. Marc Suls became his mentor, with
whom he worked for over a year before taking on a new challenge in 2018 as Head of
Orthopedics at Via Nova equine clinic.
Jan H. Spaas was born in Bilzen (Belgium) on January the 6th, 1986. His passion for horses translated in winning a 2-fold bronze medal at European Championships show jumping. He graduated as a veterinarian in 2010 at the Faculty of Veterinary Medicine of Ghent University (Belgium) and obtained his PhD in Veterinary Sciences at the same Faculty.
In 2012 he co-founded Global Stem cell Technology (acquired by Boehringer Ingelheim in 2020) to develop regenerative therapies for the treatment of musculoskeletal diseases in horses and dogs. From 2020-2024 he worked for Boehringer Ingelheim as director in global development (Athens, Georgia, US) and Global head of Research (Ingelheim, Germany).
In 2020 he was appointed visiting professor at the Department of Medical imaging of Domestic Animals and Orthopaedics of Small Animals from the Faculty of Veterinary Medicine, Ghent University. He is promotor of several PhD students, inventor of 50 patents and key author of over 40 peer-reviewed international scientific publications. He is also an Associate Editor of Frontiers in Veterinary Science for the Veterinary Regenerative Medicine.
In 2024 he made a new start in his home country Belgium as Chairman of the Board of Animab8
and co-founder of Intibio focusing on innovative orthopaedic solutions for horses.
Qualified Vet
Webinar
USD 0.00
If the options you are looking for are unavailable, please contact us.
No tax will be added unless you are a UK taxpayer
Choose currency at checkout
